Publication:
Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.

Simple item page
dc.contributor.authorGarcia-Aranda, Marilina
dc.contributor.authorTellez, Teresa
dc.contributor.authorMcKenna, Lauraine
dc.contributor.authorRedondo, Maximino
dc.contributor.funderConsejería de Transformación Económica, Industria, Conocimiento y Universidades—Junta de Andalucia
dc.contributor.funderInnovation Centers of the Public Health System of Andalusia
dc.date.accessioned2023-05-03T13:50:37Z
dc.date.available2023-05-03T13:50:37Z
dc.date.issued2022-04-30
dc.description.abstractNowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistance.
dc.description.versionSi
dc.identifier.citationGarcía-Aranda M, Téllez T, McKenna L, Redondo M. Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance. Cancers (Basel). 2022 Apr 30;14(9):2255
dc.identifier.doi10.3390/cancers14092255
dc.identifier.issn2072-6694
dc.identifier.pmcPMC9102068
dc.identifier.pmid35565383
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102068/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6694/14/9/2255/pdf?version=1652100274
dc.identifier.urihttp://hdl.handle.net/10668/20890
dc.issue.number9
dc.journal.titleCancers
dc.journal.titleabbreviationCancers (Basel)
dc.language.isoen
dc.organizationHospital Costa del Sol
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number17
dc.provenanceRealizada la curación de contenido 10/10/2025.
dc.publisherMDPI AG
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.relation.projectIDUMA20-FEDERJA-161
dc.relation.projectIDRH-0055-2020
dc.relation.publisherversionhttps://www.mdpi.com/resolver?pii=cancers14092255
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectNK-1R
dc.subjectcancer
dc.subjectdrug repurposing
dc.subjectpersonalized medicine
dc.subjectresistance
dc.subjecttachykinin
dc.subjecttachykinin receptor
dc.subjecttargeted treatment
dc.subject.decsSustancia P
dc.subject.decsReceptores de Neuroquinina-1
dc.subject.decsNeoplasias
dc.subject.decsAntagonistas de receptores de Neuroquinina-1
dc.subject.decsUso terapéutico de fármacos
dc.subject.decsResistencia a fármacos
dc.subject.decsMedicina personalizada
dc.subject.decsCáncer
dc.subject.meshSubstance P
dc.subject.meshReceptors, Neurokinin-1
dc.subject.meshNeoplasms
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshTherapeutic Equivalency as Topic
dc.subject.meshAntineoplastic Agents, Targeted
dc.titleNeurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.
dc.typereview
dc.type.hasVersionVoR
dc.volume.number14
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC9102068.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Costa del Sol
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía